The mechanisms of ERα and the modulators in skeletal muscle suggested that targeting the activation of ERα in myocyte could potentially offer therapeutic benefits for DMD, thereby presenting novel avenues for drug research targeting DMD (Figure 8). The gene discussed is ESR1; the disease is Duchenne muscular dystrophy.